Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.17
+0.50000.97%
Post-market: 52.170.00000.00%16:58 EDT
Volume:1.84M
Turnover:95.50M
Market Cap:4.51B
PE:-11.55
High:53.08
Open:52.36
Low:51.15
Close:51.67
Loading ...

CRISPR Therapeutics Ag : RBC Cuts Target Price to $38 From $48

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
03 Apr

RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
03 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Motley Fool
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers

Reuters
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

CRISPR Therapeutics (NasdaqGM:CRSP) COO Departure Announced Following 7% Share Price Decline

Simply Wall St.
·
28 Mar

CRISPR Therapeutics COO to Step Down

MT Newswires Live
·
27 Mar

Crispr Therapeutics COO Julianne Bruno to step down

TIPRANKS
·
27 Mar

Press Release: CRISPR Therapeutics Announces Transition of Chief Operating Officer

Dow Jones
·
27 Mar

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire
·
26 Mar

This CRISPR Therapeutics Insider Increased Their Holding In The Last Year

Simply Wall St.
·
26 Mar

Is CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

2 Beaten-Down Stocks to Buy on the Dip

Motley Fool
·
23 Mar

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

Zacks
·
21 Mar

Press Release: Editas Medicine Announces Chief Financial Officer Transition

Dow Jones
·
21 Mar

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

Zacks
·
19 Mar

Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?

Zacks
·
17 Mar